Skip to main content
OpenTrials
Completed

NCT Number: NCT03709602

SDH of HPV Vaccine Completion

The purpose of this research study is to find out which factors influence parents' ability to complete the human papillomavirus (HPV) vaccine series for their child. The information learned from this study may help the investigators develop programs to improve HPV vaccine completion rates among adolescents and reduce barriers to receiving the second shot of the vaccine series.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Human Papilloma Virus

Sex eligibility

All sexes

Study type

Observational

Primary location

Duke University Primary Care Pediatrics at Roxboro Road

Durham, North Carolina, 27704, United States

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • For adolescents, participants need to be between the ages 11 to 14 years.
  • Received 1 dose of the HPV vaccine series between January 2017 and December 2017.
  • For parents, there is no age limit required.
  • Parents as defined as the adolescent's biological mother or father, step-parents, or legal guardian.
  • Parents or legal guardians who self-identified as the primary caregiver of the adolescent child and most likely to make medical decisions for the adolescent.

Exclusion criteria

  • Parents with cognitive impairment.
  • Adolescents with cognitive impairment.
  • Adolescents emancipated from their parents or legal guardian
  • Pregnant adolescent girls.

Treatment and study plan

Primary outcomes

  1. Overall HPV Vaccine Completion Rates

    Time frame: up to 14 months

    Adolescents who completed the required HPV vaccine doses (e.g. two or three doses based on the CDC's vaccine administration guidelines for adolescents' ages 11 to 14 years) during the January 2017 to February 2019 observation period.

Secondary outcomes

  1. HPV Vaccine Completion Within 14-Months

    Time frame: within 14 months

    Adolescents who received the required number of doses for vaccine completion, defined as the receipt of two or three doses based on the CDC's guidelines for adolescents' ages 11 to 14 years, within 14-months from their first vaccine dose.

Sponsors and collaborators

Lead sponsor

Duke University

Other

Registry information

Official study title

Social Determinants of HPV Vaccine Completion Among Adolescents

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Oct 17, 2018
Registry last updated
Sep 1, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.